Evaluate the Efficacy of Disopyramide Therapy in Hypertrophic Obstructive Cardiomyopathy Patients

Sponsor

Rabin Medical Center (Other)

Overall Status

Unknown status

CT.gov ID

NCT02917395

Collaborator

(none)

Enrollment

Arm

Duration (Months)

Study Details

Study Description

Brief Summary

Population study- patients with obstructive hypertrophic cardiomyopathy that are treated with disopyramide.

Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.

Condition or Disease	Intervention/Treatment	Phase
Cardiomyopathy	Device: echocardiography	N/A

Detailed Description

Study Design

Study Type:

Interventional

Anticipated Enrollment :

50 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Official Title:

Evaluate the Efficacy of Disopyramide Therapy in Hypertrophic Obstructive Cardiomyopathy Patients; Comparison of Two Echocardiography Based Methods: Global Longitudinal Strain vs. Left Ventricle Ejection Fraction

Study Start Date :

Nov 1, 2016

Anticipated Primary Completion Date :

Jan 1, 2018

Anticipated Study Completion Date :

Jun 1, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: echo Population study- patients with obstructive hypertrophic cardiomyopathy that are treated with disopyramide. Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.	Device: echocardiography Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.

Arm

Intervention/Treatment

Experimental: echo

Population study- patients with obstructive hypertrophic cardiomyopathy that are treated with disopyramide. Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.

Device: echocardiography

Outcome Measures

Primary Outcome Measures

Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide [2-3 hours]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

hypertrophic cardiomyopathy that treated with disopyramid

Exclusion Criteria:

pregnancy
pacemaker

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Rabin Medical Center

Investigators

Principal Investigator: Idit Yedidya, MD, Rabin Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Idit Yedidya, Head of echo lab- hashron campus in Rabin medical center, Rabin Medical Center

ClinicalTrials.gov Identifier:

NCT02917395

Other Study ID Numbers:

0538-16-RMC

First Posted:

Sep 28, 2016

Last Update Posted:

Oct 4, 2016

Last Verified:

Oct 1, 2016

Individual Participant Data (IPD) Sharing Statement:

Undecided

Plan to Share IPD:

Undecided

Keywords provided by Idit Yedidya, Head of echo lab- hashron campus in Rabin medical center, Rabin Medical Center

hypertrophic cardiomyopathy, disopyramide,

Additional relevant MeSH terms:

Cardiomyopathies

Cardiomyopathy, Hypertrophic

Hypertrophy

Study Results

No Results Posted as of Oct 4, 2016